Drug intelligence / Profile preview

7-isopentenyloxycoumarin

Development stage
Preclinical
Modality
Small Molecules
01

Overview

**7-isopentenyloxycoumarin** is a naturally occurring oxyprenylated derivative of umbelliferone (coumarin), found in members of Rutaceae and Apiaceae (including medicinal and edible plants)[3][1]. It is characterized by a 3,3-dimethylallyl (isopentenyl) side chain at the 7-position of the coumarin core. Recent pharmacological research demonstrates diverse bioactivity: - **Anticancer**: Induces cell cycle arrest at G2/M, DNA fragmentation, chromatin condensation, increased caspase 3 activity (suggesting a proapoptotic effect), inhibition of tumor angiogenesis, and reduction of chemokine CCL2 release in tumor microenvironment. Shows cytotoxicity against certain tumor cell lines and can reverse multidrug resistance[1][3]. - **Neuroprotective**: Reduces activation of microglia and provides protection against dopaminergic neuronal cell death in models of neurodegeneration (e.g., Parkinson’s disease)[1][5]. - **Enzyme inhibition**: Potent inhibitor of butyrylcholinesterase (IC50 ~11.77 μM), with limited acetylcholinesterase activity, and notable π–π stacking interactions with butyrylcholinesterase active site[1]. - **Melanogenesis stimulator**: Significantly increases melanin biosynthesis via strong agonism of estrogen receptor β, upregulation of tyrosinase-related proteins, and microphthalmia-associated transcription factor; potential additional involvement with aryl hydrocarbon receptor[1]. - **Other properties**: Antigenotoxic (reduces DNA damage under oxidative stress), antibacterial, antifungal, antiprotozoal, anti-inflammatory, and antioxidant effects[3]. Toxicity studies demonstrate low toxicity and non-genotoxicity at tested doses[1]. No approved medical uses or commercial formulations are listed; studies are mainly in vitro and in vivo (nonclinical/preclinical).

Other names
isopentenyloxycoumarin3-(3-methylbut-3-enoxy)chromen-2-one
02

Targets

AHR (Aryl hydrocarbon receptor)ButyrylcholinesteraseESR2 (ERβ)CCL2 (C-C motif chemokine 2)

Beyond the preview

Go deeper on 7-isopentenyloxycoumarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7-isopentenyloxycoumarin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call